We are live on ! Find out more
PAI

Palo Alto Investors Portfolio holdings

AUM $654M
1-Year Est. Return 77.8%
This Fund
S&P 500
This Quarter Est. Return
-22.73%
1 Year Est. Return
+77.8%
3 Year Est. Return
+127.05%
5 Year Est. Return
+199.24%
10 Year Est. Return
+2,229.57%
AUM
$1.29B
AUM Growth
-$508M
Cap. Flow
-$29.9M
Cap. Flow %
-2.32%
Top 10 Hldgs %
71.19%
Holding
44
New
1
Increased
10
Reduced
7
Closed
–

Top Buys

Rank Stock Value
1
ACAD icon
Acadia Pharmaceuticals
ACAD
+$10.6M
2
ANAC
ANACOR PHARMACEUTICALS INC COM
ANAC
+$2.35M
3
AMAG
AMAG Pharmaceuticals
AMAG
+$1.67M
4
ENDP
Endo International plc
ENDP
+$1.29M
5
WMGI
Wright Medical Group Inc
WMGI
+$1.09M

Top Sells

Rank Stock Value
1
ABMD
Abiomed Inc
ABMD
+$47.6M
2
CLVS
Clovis Oncology, Inc.
CLVS
+$1.83M
3
STAA icon
STAAR Surgical
STAA
+$168K
4
KPTI icon
Karyopharm Therapeutics
KPTI
+$107K
5
EPZM
Epizyme, Inc
EPZM
+$55.6K

Sector Composition

Rank Sector Weight
1 Healthcare 81.45%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ABMD
1
DELISTED
Abiomed Inc
ABMD
$221M 17.12%
2,325,959
-563,546
-20% -$47.6M
UTHR icon
2
United Therapeutics
UTHR
$22.9B
$170M 13.2%
1,525,654
+7,000
+0.5% +$886K
ANAC
3
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
$119M 9.21%
2,219,042
+31,800
+1% +$2.35M
BMRN icon
4
BioMarin Pharmaceuticals
BMRN
$12.5B
$111M 8.58%
1,340,347
+3,500
+0.3% +$285K
AMAG
5
DELISTED
AMAG Pharmaceuticals
AMAG
$68M 5.28%
2,906,194
+70,402
+2% +$1.67M
CLVS
6
DELISTED
Clovis Oncology, Inc.
CLVS
$66.5M 5.16%
3,461,365
-86,354
-2% -$1.83M
INSM icon
7
Insmed
INSM
$28.9B
$60.7M 4.71%
4,790,800
– –
WMGI
8
DELISTED
Wright Medical Group Inc
WMGI
$36.4M 2.82%
2,190,957
+58,800
+3% +$1.09M
VNDA icon
9
Vanda Pharmaceuticals
VNDA
$302M
$33.7M 2.62%
4,030,908
– –
EPZM
10
DELISTED
Epizyme, Inc
EPZM
$32.2M 2.5%
2,655,479
-5,500
-0.2% -$55.6K
FOLD
11
DELISTED
Amicus Therapeutics
FOLD
$30M 2.33%
3,551,173
– –
PRTA icon
12
Prothena Corp
PRTA
$443M
$28.6M 2.22%
695,518
– –
GILD icon
13
Gilead Sciences
GILD
$165B
$27.8M 2.16%
302,900
– –
KPTI icon
14
Karyopharm Therapeutics
KPTI
$44.6M
$27.6M 2.15%
206,543
-967
-0.5% -$107K
CELG
15
DELISTED
Celgene Corp
CELG
$27.1M 2.1%
270,800
– –
MDVN
16
DELISTED
MEDIVATION, INC.
MDVN
$24.2M 1.88%
525,462
+15,600
+3% +$566K
ENDP
17
DELISTED
Endo International plc
ENDP
$23.3M 1.81%
828,630
+27,400
+3% +$1.29M
CEMP
18
DELISTED
Cempra, Inc.
CEMP
$21.3M 1.65%
1,215,833
+40,100
+3% +$727K
STAA icon
19
STAAR Surgical
STAA
$1.25B
$19.5M 1.52%
2,641,875
-24,847
-0.9% -$168K
SHPG
20
DELISTED
Shire pic
SHPG
$18.2M 1.42%
106,100
+1,400
+1% +$234K
ZLTQ
21
DELISTED
ZELTIQ Aesthetics, Inc.
ZLTQ
$15.6M 1.21%
573,636
– –
ARIA
22
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$14.4M 1.12%
2,248,317
-8,900
-0.4% -$49.9K
SQNM
23
DELISTED
SEQUENOM INC NEW
SQNM
$14.1M 1.1%
10,023,842
– –
MNTA
24
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$13.6M 1.05%
1,468,776
– –
ACAD icon
25
Acadia Pharmaceuticals
ACAD
$5.01B
$13.6M 1.05%
+485,100
New +$10.6M
1
2

Similar funds

RRA
Round Rock Advisors Wilton, Connecticut $654M AUM 22.95% 1-Year Est. Return
W
WPWealth Fort Worth, Texas $654M AUM 13.19% 1-Year Est. Return
DAS
Diversify Advisory Services Sandy, Utah $655M AUM 24.57% 1-Year Est. Return
AG
Alibaba Group Causeway Bay, Hong Kong $653M AUM 16.11% 1-Year Est. Return
BL
BWCP LP Dallas, Texas $656M AUM 41.58% 1-Year Est. Return
CG
CFO4Life Group Coppell, Texas $656M AUM 17.88% 1-Year Est. Return
SCM
Stevens Capital Management Radnor, Pennsylvania $649M AUM 27.37% 1-Year Est. Return
GAMA
Graticule Asia Macro Advisors New York $649M AUM

Palo Alto Investors's Q1 2016 Portfolio in Review

As of Q1 2016, Palo Alto Investors held 44 positions worth $1.29B, down 28% from $1.8B the previous quarter. Its ten largest holdings account for 71% of the portfolio.

Trading was light in Q1 2016: portfolio turnover was 2.3%. Palo Alto Investors opened 1 new position and made no exits, leaving the 44-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 81% of assets, up from 78% a quarter earlier.

  • Palo Alto Investors's largest Q1 2016 buy was Acadia Pharmaceuticals: 485,100 shares worth $13.6M.
  • Palo Alto Investors added most to ANACOR PHARMACEUTICALS INC COM in Q1 2016, an estimated $2.35M increase.
  • Palo Alto Investors's biggest Q1 2016 reduction was Abiomed Inc, cutting an estimated $47.6M.
  • Palo Alto Investors's ten largest holdings make up 71% of its $1.29B portfolio in Q1 2016.
  • Palo Alto Investors opened 1 new position and closed 0 in Q1 2016.
  • Palo Alto Investors's portfolio value fell 28% quarter-over-quarter to $1.29B.

Based on Palo Alto Investors's 13F filing for Q1 2016, filed 16 May 2016.